Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Melanoma 9Carcinoma, Renal Cell 8Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Leukemia 2Kidney Neoplasms 2Colorectal Neoplasms 2Uveal Melanoma 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1

Interventions

Dexamethasone 337Bortezomib 187Lenalidomide 186Cyclophosphamide 166Melphalan 124Calcium Dobesilate 108daratumumab 95fludarabine phosphate 69carfilzomib 69pomalidomide 68Peripheral Blood Stem Cell Transplantation 64Filgrastim 56Thalidomide 55Busulfan 53Mycophenolic Acid 52Tacrolimus 45Granulocyte Colony-Stimulating Factor 45ixazomib 43fludarabine 42Whole-Body Irradiation 40Cyclosporine 35Etoposide 33dexamethasone acetate 31Antilymphocyte Serum 31isatuximab 29dexamethasone 21-phosphate 26Prednisone 26elotuzumab 25Biopsy 25auricularum 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Multiple Myeloma × Introns × Clear all
NCT00004088 2019-07-02

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

City of Hope Medical Center

Phase 2 Completed
77 enrolled 15 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00006244 2017-07-12

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 2 Completed
36 enrolled 14 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡